Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

IND Swift Laboratories Ltd

INDSWFTLAB.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$3.19

▲ +2.55%

Market Cap $277.16M · Vol 618.96K

Key Metrics

P/E Ratio

45.47

FWD: N/A

Market Cap

$277.16M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

76.99

Momentum

Beta

0.91

vs Market

52W High

$3.36

5.20% below

52W Low

$0.91

228.59% above

Volume

618.96K

Avg 1.35M

P/B

0.82

Price-to-book

ROE

N/A

Return on equity

Free Float

36.27%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, IND Swift Laboratories Ltd (INDSWFTLAB.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INDSWFTLAB.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+33.17%

+32.33%

+125.97%

+123.56%

YTD

+245.07%

+199.86%

+194.20%

+291.48%

Financials & Valuation

TTM · Annual

Total Revenue	$68.62M
Net Income	$4.42M
Revenue Growth (YoY)	+25.35%
Gross Margin	51.18%
Operating Margin	2.26%
Net Profit Margin	6.46%
ROE	N/A
ROA · ROIC	3.15% · 3.25%

P/E Ratio	45.47
Forward P/E (FY1)	N/A
PEG Ratio	-0.31
P/S	1.75
P/B	0.82
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	86.96M

Technical Indicators

50-Day SMA	$2.26
200-Day SMA	$1.51
RSI (14)	76.99
Beta	0.91
52-Week High	$3.36
52-Week Low	$0.91

Volume Today	618.96K
Avg Daily Volume (30D)	1.35M
Relative Volume	0.46x
Volatility (10D)	86.13
Volatility (30D)	67.89
Free Float	36.27%

Analyst Consensus

N/A

Current Price $3.19

Mean Target N/A

52W Low$0.91 52W High$3.36

Current

Target

$0.91 $3.36

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S88GX9

ISININE915B01019

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd -0.10% 4578.T Otsuka Holdings Co Ltd -3.26% CIPLA.NS Cipla Ltd -0.60% ZYDUSLIFE.NS Zydus Lifesciences Ltd -2.75% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt +1.56%

Company Profile

Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.